Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE In cystic fibrosis-related liver disease, lack of cystic fibrosis transmembrane conductance regulator increases the sensitivity of epithelial Toll-like receptor 4 that sustains the secretion of nuclear factor-κB-dependent cytokines and peribiliary inflammation in response to gut-derived products, providing a model for primary sclerosing cholangitis. 31165788 2019
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE Patients with PSC underwent nasal potential difference (NPD) measurement, sweat chloride measurement and complete CFTR sequencing by new generation sequencing. 29807875 2018
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE In this cohort of PSC patients, several CFTR-variants affecting the functional properties of the CFTR protein seem to offer protection against the development of PSC, confirming our hypothesis that CFTR might be implicated in the pathogenesis of PSC. 18992954 2009
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE There is a high prevalence of CFTR-mediated ion transport dysfunction in subjects with childhood PSC. 17719933 2007
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE As proof of concept that CFTR dysfunction plays a role in PSC, induction of colitis in cftr mice results in bile duct injury that can be prevented by pretreatment with docosahexaenoic acid (DHA). 16540796 2006
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE These data suggest that CFTR dysfunction does not influence the pathogenesis of PSC. 15784035 2005
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE These data indicate that there is an increased prevalence of CFTR abnormalities in PSC as demonstrated by molecular and functional analyses and that these abnormalities may contribute to the development of PSC in a subset of patients with inflammatory bowel disease. 12783301 2003
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 Biomarker disease BEFREE Our results show that: (1) tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma, synergically stimulate NO production in cultured cholangiocytes through an increase in NOS2 gene and protein expression; (2) micromolar concentrations of NO inhibit forskolin-stimulated cAMP production by adenylyl cyclase (AC), cyclic adenosine monophosphate (cAMP)-dependent fluid secretion, and cAMP-dependent Cl(-) and HCO(3)(-) transport mediated by cystic fibrosis transmembrane conductance regulator (CFTR) and anion exchanger isoform 2, respectively; (3) cholestatic effects of NO and of proinflammatory cytokines are prevented by NOS-2 inhibitors and by agents (manganese(III)-tetrakis(4-benzoic acid)porphyrin [MnTBAP], urate, trolox) able to block the formation of reactive nitrogen oxide species (RNOS); (4) NOS2 expression is increased significantly in the biliary epithelium of patients with primary sclerosing cholangitis (PSC). 12612912 2003
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 GeneticVariation disease BEFREE The possibility that CFTR mutations may contribute to a severe clinical course in PSC patients is worth further examining. 12127423 2002
CUI: C0566602
Disease: Primary sclerosing cholangitis
Primary sclerosing cholangitis
0.100 GeneticVariation disease BEFREE Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. 8617131 1996